Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.77% | 13.38% | -13.23% | 27.63% | -58.74% |
| Total Depreciation and Amortization | -8.85% | -3.94% | 0.61% | -4.38% | 5.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 227.84% | 4.59% | -21.07% | -6.23% | -11.73% |
| Change in Net Operating Assets | -162.68% | -25.61% | 217.06% | -155.00% | 1,129.02% |
| Cash from Operations | 16.78% | 12.37% | 26.92% | -24.36% | -16.99% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | 19,700.00% | -99.50% | 96.94% | 2.24% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.08% | 465.18% | -137.88% | 165.94% | 6.70% |
| Cash from Investing | -34.45% | 488.66% | -135.19% | 167.21% | 7.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -50.07% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | -41.26% | -727.19% | -- | -100.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.56% | 118.05% | -132.69% | 76.10% | -2.68% |